National Bank of Canada
ABCL icon

National Bank of Canada’s AbCellera Biologics ABCL Stock Holding History

National Bank of Canada’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-540
Closed -$158K – 2828
2024
Q4 		$158K Sell
540
-2
-0.4% -$6 ﹤0.01% 1661
2024
Q3 		$141K Hold
542
– – ﹤0.01% 1458
2024
Q2 		$151K Sell
542
-1,466
-73% -$5.55K ﹤0.01% 1391
2024
Q1 		$769K Buy
+2,008
New +$10.2K ﹤0.01% 1177

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

National Bank of Canada's ABCL Position: Q1 2026 in Review

National Bank of Canada opened a new position in AbCellera Biologics (ABCL) in Q1 2026: 1,393 shares worth $4.86K. The stake represents ﹤0.01% of the portfolio and ranks #2464 among its holdings. This is a return to the name: National Bank of Canada previously reported a position in ABCL as recently as Q3 2025.

National Bank of Canada first reported a position in ABCL in Q4 2021 and has held it in 17 quarters since. The position peaked at $704K in Q1 2024. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • National Bank of Canada held 1,393 shares of AbCellera Biologics worth $4.86K as of Q1 2026.
  • AbCellera Biologics was a new National Bank of Canada position in Q1 2026.
  • AbCellera Biologics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2464 holding.
  • National Bank of Canada first reported a position in AbCellera Biologics in Q4 2021 and has held it in 17 quarters since.
  • National Bank of Canada's AbCellera Biologics position peaked at $704K in Q1 2024.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.